Health Act 1947 (Section 31A - Temporary Restrictions) (Covid-19) (Restrictions Upon Travel to the State from Certain States) (No. 5) (Amendment) (No. 8) Regulations 2021.
Statutory Instruments
Source: Statutory Instruments

num: 1
paragraphs: (1) These Regulations may be cited as the Health Act 1947 (Section 31A - Temporary Restrictions) (Covid-19) (Restrictions upon Travel to the State from Certain States) (No. 5) (Amendment) (No. 8) Regulations 2021.
(2) These Regulations shall come into operation on the 17th day of December 2021.
num: 2
paragraphs: In these Regulations, “Principal Regulations” means the Health Act 1947 (Section 31A - Temporary Restrictions) (Covid-19) (Restrictions upon Travel to the State from Certain States) (No. 5) Regulations 2021 ( S.I. No. 135 of 2021 ).
num: 3
paragraphs: Regulation 2 of the Principal Regulations is amended –
(a) in the definition of “relevant test result”, by the substitution of the following subparagraph for subparagraph (ii) of paragraph (b):
“(ii) confirming that –
(I) the person has been subject to a RT-PCR test or a rapid antigen test,
(II) such test was administered to the person –
(A) in the case of a RT-PCR test, no more than 72 hours before the person arrives in the State, and
(B) in the case of a rapid antigen test, no more than 48 hours before the person arrives in the State, and
(III) Covid-19, or the virus SARS-CoV-2, was not detected in the person at the time of taking the test, or”,
and
(b) in the definition of “vaccinated person” –
(i) by the insertion of the following paragraph after paragraph (f):
“(fa) a person to whom the medicinal product for active immunisation to prevent Covid-19 known as ‘Bharat Biotech BBV152’, also known as ‘COVAXIN’, has been administered such that the second dose of the medicinal product concerned has been administered to the person not less than 14 days before his or her arrival in the State,”,
(ii) in paragraph (g) –
(I) by the substitution of “(e), (f) and (fa)” for “(e) and (f)”,
(II) in subparagraph (iv), by the substitution of “in the State,” for “in the State, or”, and
(III) by the insertion of the following subparagraph after subparagraph (v):
“(vi) in the case of the second dose being the medicinal product referred to in paragraph (fa), not less than 14 days before his or her arrival in the State, or”,
and
(iii) in paragraph (h), by the substitution of “(e), (f) or (fa)” for “(e) or (f)”.
num: 4
paragraphs: Regulation 7A is amended by the substitution of the following definition for the definition of “applicable test result”:
(a) in relation to a person other than a person referred to in paragraph (b), any record or evidence, in written or electronic form, confirming that –
(i) the person has been subject to a RT-PCR test,
(ii) such test was administered to the person no more than 72 hours before the person arrives in the State, and
(iii) Covid-19, or the virus SARS-CoV-2, was not detected in the person at the time of taking the test, or
(b) in relation to a person who has been infected with Covid-19, or the virus SARS-CoV-2, any record or evidence, in written or electronic form –
(i) confirming that –
(I) the person has been subject to a RT-PCR test,
(II) such RT-PCR test was administered to the person no less than 11 days prior to the date on which the person arrives in the State and no more than 180 days prior to the date on which the person so arrives, and
(III) Covid-19, or the virus SARS-CoV-2, was detected in the person at the time of taking the RT-PCR test, and
(ii) confirming that –
(I) the person has been subject to a RT-PCR test or a rapid antigen test,
(II) such test was administered to the person –
(A) in the case of a RT-PCR test, no more than 72 hours before the person arrives in the State, or
(B) in the case of a rapid antigen test, no more than 48 before the person arrives in the State, and
(III) Covid-19, or the virus SARS-CoV-2, was not detected in the person at the time of taking the test.”.